Follicular Lymphoma Pipeline Analysis: 30+ Key Companies Advancing 50+ Pipeline Therapies for Follicular Lymphoma Treatment | DelveInsight

DelveInsight's Follicular Lymphoma Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Follicular Lymphoma therapies in various stages of clinical development. Major pharmaceutical companies are actively working to advance the Follicular Lymphoma pipeline space and improve future treatment opportunities for patients with Follicular Lymphoma.

Key takeaways from the Follicular Lymphoma Clinical Trial Landscape Report
• DelveInsight's Follicular Lymphoma pipeline report depicts a robust space with 30+ active players working to develop 50+ pipeline therapies for Follicular Lymphoma treatment.
• Key Follicular Lymphoma companies such as AstraZeneca, Xynomic Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Nurix Therapeutics, Inc., Carna Biosciences, Inc., Bristol-Myers Squibb, and others are evaluating novel treatment approaches.
• Promising Follicular Lymphoma pipeline therapies in various stages of development include AZD0486, Abexinostat, SHR 2554, NX-2127, AS-1763, and Golcadomide.

Request a sample and discover the recent advances in Follicular Lymphoma treatment drugs at: https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Follicular Lymphoma?
Follicular lymphoma (FL) is the second most common type of non-Hodgkin lymphoma and represents one of the most prevalent forms of indolent B-cell lymphomas. It arises from germinal center B cells and is characterized by slow progression and prolonged survival in many patients. Histologically, FL is graded from 1 to 3 based on the number of centroblasts, with grade 3B showing more aggressive behavior similar to diffuse large B-cell lymphoma.
Common symptoms of Follicular Lymphoma include painless swollen lymph nodes, fatigue, fever, night sweats, weight loss, abdominal discomfort, and recurrent infections. Diagnosis involves excisional lymph node biopsy, immunophenotyping, imaging, and molecular testing. Current treatment options include radiotherapy, immunochemotherapy, rituximab-based therapies, bendamustine combinations, and stem cell transplantation in selected cases.

Emerging Follicular Lymphoma Drug Profiles

AZD0486: AstraZeneca
AZD0486 (formerly TNB-486) is a novel IgG4 fully human CD19xCD3 bispecific T-cell engager designed to reduce cytokine release while maintaining potent T-cell-mediated cytotoxicity against malignant B cells. The therapy is currently being evaluated in Phase III clinical development for Follicular Lymphoma treatment.
In August 2024, AstraZeneca initiated a Phase III randomized study evaluating AZD0486 plus rituximab versus chemotherapy plus rituximab in untreated Follicular Lymphoma patients. The study is expected to enroll 1,015 participants globally.

Abexinostat: Xynomic Pharmaceuticals
Abexinostat is an oral histone deacetylase inhibitor under clinical investigation for Follicular Lymphoma. The therapy is currently in Phase II development and is being explored for its role in relapsed or refractory lymphoma indications.

Learn more about the novel and emerging Follicular Lymphoma pipeline therapies at: https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Follicular Lymphoma Clinical Trial Landscape
• In February 2026, AstraZeneca's surovatamig received Orphan Drug Designation from the FDA for the treatment of Follicular Lymphoma.
• In November 2025, Tempus AI, Inc. announced a new research collaboration with the Institute for Follicular Lymphoma Innovation (IFLI) to accelerate innovative treatment options for Follicular Lymphoma patients.
• In October 2025, Verismo Therapeutics treated the first Follicular Lymphoma patient in its CELESTIAL-301 Phase I clinical trial of SynKIRTM-310.
• In January 2025, Verismo Therapeutics announced a strategic investment from IFLI to support development of its SynKIRTM-310 pipeline for Follicular Lymphoma.
• In January 2025, Catalent, Inc. entered a strategic collaboration with Galapagos NV to support decentralized manufacturing for GLPG5101 clinical studies in relapsed/refractory non-Hodgkin lymphoma indications.

Scope of the Follicular Lymphoma Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Preclinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Parenteral, Subcutaneous, Intratumoral
• Therapeutics Assessment By Molecule Type: Antibody, Antibody Drug Conjugate, CAR-T Cell Therapy, Gene Therapy, Immunotherapy, Recombinant Fusion Protein, Small Molecule, and others
• Key Follicular Lymphoma Companies: AstraZeneca, Xynomic Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Nurix Therapeutics, Inc., Carna Biosciences, Inc., and others
• Key Follicular Lymphoma Pipeline Therapies: AZD0486, Abexinostat, SHR 2554, NX-2127, AS-1763, Golcadomide, and others

Dive deep into rich insights for new drugs for Follicular Lymphoma treatment at: https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Follicular Lymphoma Pipeline Report Introduction
2. Follicular Lymphoma Pipeline Report Executive Summary
3. Follicular Lymphoma: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Follicular Lymphoma Pipeline Therapeutics
6. Follicular Lymphoma Pipeline: Late Stage Products
7. Follicular Lymphoma Pipeline: Mid Stage Products
8. Follicular Lymphoma Pipeline: Early Stage Products
9. Follicular Lymphoma Pipeline Therapeutics Assessment
10. Inactive Products in the Follicular Lymphoma Pipeline
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products in the Follicular Lymphoma Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

For further information on the Follicular Lymphoma pipeline therapeutics, reach out to DelveInsight at https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve

This release was published on openPR.